Inhibition of endotoxic lipopolysaccharide-mediated platelet aggregation by cobra venom anticomplementary factor.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D000936:Antigen-Antibody Complex; D003094:Collagen / Q000494:pharmacology; D003168:Complement Fixation Tests; D003169:Complement Inactivator Proteins; D003720:Densitometry; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins / Q000037:antagonists & inhibitors*; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D006461:Hemolysis; D006358:Hot Temperature; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors*; D008297:Male; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D011135:Polysaccharides, Bacterial / Q000037:antagonists & inhibitors*; D011817:Rabbits; D012485:Salmonella typhi / Q000276:immunology; D012486:Salmonella typhimurium / Q000276:immunology; D012706:Serratia marcescens / Q000276:immunology; D012911:Snakes; D013997:Time Factors; D014688:Venoms / Q000008:administration & dosage / Q000494:pharmacology*; D015054:Zymosan / Q000494:pharmacology
D000936:Antigen-Antibody Complex; D003169:Complement Inactivator Proteins; D004731:Endotoxins; D008070:Lipopolysaccharides; D011135:Polysaccharides, Bacterial; D014688:Venoms; D000244:Adenosine Diphosphate; D003094:Collagen; D015054:Zymosan